At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 48 enrolled
Drug / intervention
Baxdrostat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo-controlled Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone Stimulation Test Following Treatment With Baxdrostat for 8 Weeks in Participants With Uncontrolled Hypertension
In Brief
A Phase 2 clinical trial evaluating Baxdrostat and Placebo for Uncontrolled Hypertension. Completed, enrolled 48 participants across 10 sites.
Detailed Summary
The main purpose of this study is to assess the serum free cortisol response after ACTH stimulation test at baseline and at Week 8 in participants with uncontrolled hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUncontrolled Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20252026
First PostedMar 2024
Enrollment StartJun 2024
Primary CompletionDec 2024
TodayJul 2026
First PostedMar 28, 2024
Enrollment StartJun 10, 2024
Primary CompletionDec 4, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.3 years ago
Interventions
Baxdrostatdrug
Baxdrostat will be administered orally once daily.
Placebodrug
Placebo will be administered orally once daily.